Big Data Medicine Pharma Companies 
Pharmaceutical Technology
JANUARY 16, 2023
The report also suggested that Big Data was thought to be the most important partner to AI, in terms of introducing technology-related changes in the pharmaceutical sector (Figure 2). In addition to collaborating with AI-technology providers, pharma companies are also engaging in vertical integration.
Pharma Marketing Network
JANUARY 29, 2025
With machine learning and big data analytics, companies can now predict market trends, enhance drug development, and create hyper-personalized campaigns. Big data analytics plays a crucial role in identifying prescribing patterns, understanding patient behaviors, and tailoring content strategies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 1, 2022
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
pharmaphorum
SEPTEMBER 18, 2020
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.
pharmaphorum
MARCH 19, 2021
The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,
pharmaphorum
DECEMBER 22, 2021
For the past ten years we’ve seen a steady acceptance of the need for patient engagement practises to become routine and integrated into all systems of healthcare and the creation of new medicines and devices. Patients are beginning to expect the providers of their medicines to help them with their condition and the impact on their lives.
pharmaphorum
JULY 14, 2022
It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements. “Access to raw data can assist regulators in understanding the submitted evidence and therefore inform the regulatory decisions on the benefit-risk balance of the product,” it continues.
Expert insights. Personalized for you.
303 
Let's personalize your content